OFG
CORT icon

Oxford Financial Group’s Corcept Therapeutics CORT Stock Holding History

Oxford Financial Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-206,982
Closed -$5.42M – 223
2020
Q4 		$5.42M Sell
206,982
-130,454
-39% -$2.75M 0.78% 21
2020
Q3 		$5.87M Buy
337,436
+5,000
+2% +$79.7K 0.95% 19
2020
Q2 		$5.59M Hold
332,436
– – 0.95% 19
2020
Q1 		$3.95M Buy
+332,436
New +$4.11M 0.79% 21

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxford Financial Group's CORT Position: Q1 2021 in Review

Oxford Financial Group sold out of Corcept Therapeutics (CORT) in Q1 2021, closing a stake of 206,982 shares — an estimated $5.42M sold.

Oxford Financial Group first reported a position in CORT in Q1 2020 and held it in 4 quarters. The position peaked at $5.87M in Q3 2020. 209 funds tracked by Wall St. Rank hold CORT as of Q1 2021.

  • Oxford Financial Group reported no remaining Corcept Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Oxford Financial Group sold 206,982 Corcept Therapeutics shares in Q1 2021, an estimated $5.42M.
  • Oxford Financial Group first reported a position in Corcept Therapeutics in Q1 2020 and held it in 4 quarters.
  • Oxford Financial Group's Corcept Therapeutics position peaked at $5.87M in Q3 2020.
  • 209 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2021.

Based on Oxford Financial Group's 13F filing for Q1 2021, filed 10 May 2021.